The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care
Identifieur interne : 000524 ( Pmc/Corpus ); précédent : 000523; suivant : 000525The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care
Auteurs : Francesca De FeliceSource :
- Radiotherapy and Oncology [ 0167-8140 ] ; 2020.
Url:
DOI: 10.1016/j.radonc.2020.03.020
PubMed: 32247204
PubMed Central: 7138158
Links to Exploration step
PMC:7138158Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care</title><author><name sortKey="De Felice, Francesca" sort="De Felice, Francesca" uniqKey="De Felice F" first="Francesca" last="De Felice">Francesca De Felice</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32247204</idno><idno type="pmc">7138158</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138158</idno><idno type="RBID">PMC:7138158</idno><idno type="doi">10.1016/j.radonc.2020.03.020</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000524</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000524</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care</title><author><name sortKey="De Felice, Francesca" sort="De Felice, Francesca" uniqKey="De Felice F" first="Francesca" last="De Felice">Francesca De Felice</name></author></analytic><series><title level="j">Radiotherapy and Oncology</title><idno type="ISSN">0167-8140</idno><idno type="eISSN">1879-0887</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Pignon, J P" uniqKey="Pignon J">J.P. Pignon</name></author><author><name sortKey="Le Maitre, A" uniqKey="Le Maitre A">A. le Maître</name></author><author><name sortKey="Maillard, E" uniqKey="Maillard E">E. Maillard</name></author><author><name sortKey="Bourhis, J" uniqKey="Bourhis J">J. Bourhis</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Remuzzi, A" uniqKey="Remuzzi A">A. Remuzzi</name></author><author><name sortKey="Remuzzi, G" uniqKey="Remuzzi G">G. Remuzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blanchard, P" uniqKey="Blanchard P">P. Blanchard</name></author><author><name sortKey="Bourhis, J" uniqKey="Bourhis J">J. Bourhis</name></author><author><name sortKey="Lacas, B" uniqKey="Lacas B">B. Lacas</name></author><author><name sortKey="Posner, M R" uniqKey="Posner M">M.R. Posner</name></author><author><name sortKey="Vermorken, J B" uniqKey="Vermorken J">J.B. Vermorken</name></author><author><name sortKey="Cruz Hernandez, J J" uniqKey="Cruz Hernandez J">J.J. Cruz Hernandez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Overgaard, J" uniqKey="Overgaard J">J. Overgaard</name></author><author><name sortKey="Hansen, H S" uniqKey="Hansen H">H.S. Hansen</name></author><author><name sortKey="Specht, L" uniqKey="Specht L">L. Specht</name></author><author><name sortKey="Overgaard, M" uniqKey="Overgaard M">M. Overgaard</name></author><author><name sortKey="Grau, C" uniqKey="Grau C">C. Grau</name></author><author><name sortKey="Andersen, E" uniqKey="Andersen E">E. Andersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Terhaard, C H" uniqKey="Terhaard C">C.H. Terhaard</name></author><author><name sortKey="Lubsen, H" uniqKey="Lubsen H">H. Lubsen</name></author><author><name sortKey="Rasch, C R" uniqKey="Rasch C">C.R. Rasch</name></author><author><name sortKey="Levendag, P C" uniqKey="Levendag P">P.C. Levendag</name></author><author><name sortKey="Kaanders, H H" uniqKey="Kaanders H">H.H. Kaanders</name></author><author><name sortKey="Tjho Heslinga, R E" uniqKey="Tjho Heslinga R">R.E. Tjho-Heslinga</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="letter"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Radiother Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Radiother Oncol</journal-id><journal-title-group><journal-title>Radiotherapy and Oncology</journal-title></journal-title-group><issn pub-type="ppub">0167-8140</issn><issn pub-type="epub">1879-0887</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32247204</article-id><article-id pub-id-type="pmc">7138158</article-id><article-id pub-id-type="publisher-id">S0167-8140(20)30151-1</article-id><article-id pub-id-type="doi">10.1016/j.radonc.2020.03.020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>De Felice</surname><given-names>Francesca</given-names></name><email>fradefelice@hotmail.it</email><xref rid="cor1" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="af005">Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Viale Regina Elena 326, 00161 Rome, Italy</aff><contrib-group><contrib contrib-type="author" id="au010"><name><surname>Polimeni</surname><given-names>Antonella</given-names></name></contrib></contrib-group><aff id="af010">Department of Oral and Maxillo Facial Sciences, Policlinico Umberto I, “Sapienza” University of Rome, Via Caserta 6, 00161 Rome, Italy</aff><contrib-group><contrib contrib-type="author" id="au015"><name><surname>Valentini</surname><given-names>Vincenzo</given-names></name></contrib></contrib-group><aff id="af015">Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Viale Regina Elena 326, 00161 Rome, Italy</aff><author-notes><corresp id="cor1"><label>⁎</label>Address: Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Viale Regina Elena 326, 00161 Rome, Italy. <email>fradefelice@hotmail.it</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>24</day><month>3</month><year>2020</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>3</month><year>2020</year></pub-date><volume>147</volume><fpage>84</fpage><lpage>85</lpage><history><date date-type="received"><day>19</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>20</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>© 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><kwd-group id="kg005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Coronavirus</kwd><kwd>Head neck cancer</kwd><kwd>Radiotherapy</kwd><kwd>Surgery</kwd><kwd>Chemotherapy</kwd><kwd>Care</kwd><kwd>Treatment</kwd></kwd-group></article-meta></front><body><p id="p0005">To monitor and defeat further progression of the novel Coronavirus (COVID-19) infection, a strong public health vigilance has been adopted in Italy <xref rid="b0005" ref-type="bibr">[1]</xref>. By March 18, 31,772 cases were confirmed, with 2390 deaths <xref rid="b0010" ref-type="bibr">[2]</xref>. The median age of patients who are infected is 63 years and more than two-thirds of deaths have occurred in elderly patients (aged ≥70 years) <xref rid="b0010" ref-type="bibr">[2]</xref>. Hospitals’ work regimes have been re-prioritized, but Coronavirus does not really affect the cancer clinics. Although radiation oncologists are not fighting on the front line, they have to guarantee treatment – radiotherapy with or without concomitant chemotherapy ((C)RT) – and, in the meantime, protect patients from the COVID-19 infection.</p><p id="p0010">In this scenario, (C)RT has a crucial role in head and neck cancer (HNC) management. It is the mainstay of treatment for most of the HNC sites, because of its proven curative intent assuring an organ preservation strategy <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. HNC is a relatively rare cancer in Italy, with 9300 new cases and 3216 deaths described per year <xref rid="b0025" ref-type="bibr">[5]</xref>. Most of the patients are diagnosed in a locally advanced stage disease and should receive treatment as soon as possible. Therefore, during this pandemic period, HNC patients represent a major clinical problem with treatment decision-making process. Due to the complexity in optimal strategy plan and patients’ support care through treatment, the multidisciplinary team should weigh the risks and the benefits to patients in deciding whether to modify patients’ work-up and treatment approach. We cannot provide specific guidance on any other protocol of therapy – at this time, no clinical HNC-specific data on COVID-19 are available – but we can state that each decision requires an individualized risk/benefit assessment. The aim should be to protect HNC patients without compromising their oncologic outcome. It is paramount to stress open channels of communication between administrators, clinicians, patients and caregivers <xref rid="b0030" ref-type="bibr">[6]</xref>. In order to assist shared decision-making, multidisciplinary team meetings should be promoted using web-platforms. A reasonable treatment strategy between anticancer therapy and epidemic prevention should be selected. It should be considered to: i) omit systemic therapy for patients ≥70 years or younger with co-morbidities, such as diabetes and cardiovascular diseases. On the one hand, the updated meta-analysis of chemotherapy in head and neck cancer (MACH-NC) did not show any survival benefit resulting from the addition of chemotherapy for elderly patients <xref rid="b0015" ref-type="bibr">[3]</xref>. On the other hand, these relevant co-morbidities are linked to a higher risk of death in case of COVID-19 infection <xref rid="b0035" ref-type="bibr">[7]</xref>. ii) omit cisplatin-based induction chemotherapy. A definitive benefit in overall survival with the incorporation of induction chemotherapy compared to standard (C)RT has not been proven in randomized studies <xref rid="b0040" ref-type="bibr">[8]</xref>. iii) short overall treatment time. Definitive (C)RT should be limited to simultaneous integrated boost (SIB) techniques in the standard (5 fractions per week) or accelerated schedule (6 fractions per week), in order to achieve a 1-week reduction compared to sequential technique. SIB technique represents an optimum balance between tumor control and prevention of late toxicity excess <xref rid="b0045" ref-type="bibr">[9]</xref>. iv) delay post-operative RT in patients with salivary gland tumors until 12 weeks after surgery. Time factor is not strictly linked to adverse effect in these cases <xref rid="b0050" ref-type="bibr">[10]</xref>. v) develop an online surveillance plan. At present HNC patients deal with the double ordeals of disease and pandemic situation. Patients should be educated to properly identify those symptoms and signs that potentially signify a recurrence (increased local pain and difficulty in swallowing, unexplained weight loss and development of new lump in the head and neck region). For sure, patients should be informed regarding the Coronavirus symptoms (mainly fever, dyspnea and cough) and educated in proper hand washing and all other measures to limit viral transmission (avoid touching your eyes, nose and mouth; cover your nose and mouth with a tissue when you cough or sneeze; clean and disinfect high touch surfaces regularly; stop shaking hands or kissing as a greeting; reduce exposure to sick contacts and large crowds). Psychological counseling should be paid attention to through seeking alternative schemes.</p><p id="p0015">It must be appreciated that this document is an attempt to provide practical suggestions on how to define a reasonable treatment strategy and mitigate the COVID-19 impact on HNC patients under the current pandemic conditions. It is necessary to offer adequate individualized treatment recommendations based on both the epidemic situation and the patient's own condition. We significantly hope to help HNC patients to survive this difficult period.</p></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><mixed-citation publication-type="other" id="h0005"><ext-link ext-link-type="uri" xlink:href="https://www.gazzettaufficiale.it" id="ir005">https://www.gazzettaufficiale.it</ext-link></mixed-citation></ref><ref id="b0010"><label>2</label><mixed-citation publication-type="other" id="h0010"><ext-link ext-link-type="uri" xlink:href="https://www.epicentro.iss.it/coronavirus/bollettino" id="ir010">https://www.epicentro.iss.it/coronavirus/bollettino</ext-link></mixed-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Pignon</surname><given-names>J.P.</given-names></name><name><surname>le Maître</surname><given-names>A.</given-names></name><name><surname>Maillard</surname><given-names>E.</given-names></name><name><surname>Bourhis</surname><given-names>J.</given-names></name></person-group><article-title>MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients</article-title><source>Radiother Oncol</source><volume>92</volume><issue>1</issue><year>2009</year><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">19446902</pub-id></element-citation></ref><ref id="b0020"><label>4</label><mixed-citation publication-type="other" id="h0020">National Comprehensive Cancer Network (NCCN). Guidelines Head and Neck Cancers, Version 1.2020. available at http://www.nccn.org.</mixed-citation></ref><ref id="b0025"><label>5</label><mixed-citation publication-type="other" id="h0025">AIOM (2019). AIRTUM. I numeri del cancro in Italia. Il Pensiero Scientifico; 2019.</mixed-citation></ref><ref id="b0030"><label>6</label><mixed-citation publication-type="other" id="h0030">National Comprehensive Cancer Network (NCCN). How to Manage Cancer Care during COVID-19 Pandemic. available at http://www.nccn.org.</mixed-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Remuzzi</surname><given-names>A.</given-names></name><name><surname>Remuzzi</surname><given-names>G.</given-names></name></person-group><article-title>COVID-19 and Italy: what next?</article-title><source>Lancet</source><year>2020</year><comment>pii: S0140-6736(20)30627-9</comment></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>P.</given-names></name><name><surname>Bourhis</surname><given-names>J.</given-names></name><name><surname>Lacas</surname><given-names>B.</given-names></name><name><surname>Posner</surname><given-names>M.R.</given-names></name><name><surname>Vermorken</surname><given-names>J.B.</given-names></name><name><surname>Cruz Hernandez</surname><given-names>J.J.</given-names></name></person-group><article-title>Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group</article-title><source>J Clin Oncol</source><volume>31</volume><issue>23</issue><year>2013</year><fpage>2854</fpage><lpage>2860</lpage><pub-id pub-id-type="pmid">23835714</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Overgaard</surname><given-names>J.</given-names></name><name><surname>Hansen</surname><given-names>H.S.</given-names></name><name><surname>Specht</surname><given-names>L.</given-names></name><name><surname>Overgaard</surname><given-names>M.</given-names></name><name><surname>Grau</surname><given-names>C.</given-names></name><name><surname>Andersen</surname><given-names>E.</given-names></name></person-group><article-title>Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial</article-title><source>Lancet</source><volume>362</volume><issue>9388</issue><year>2003</year><fpage>933</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">14511925</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Terhaard</surname><given-names>C.H.</given-names></name><name><surname>Lubsen</surname><given-names>H.</given-names></name><name><surname>Rasch</surname><given-names>C.R.</given-names></name><name><surname>Levendag</surname><given-names>P.C.</given-names></name><name><surname>Kaanders</surname><given-names>H.H.</given-names></name><name><surname>Tjho-Heslinga</surname><given-names>R.E.</given-names></name></person-group><article-title>The role of radiotherapy in the treatment of malignant salivary gland tumors</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>61</volume><issue>1</issue><year>2005</year><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">15629600</pub-id></element-citation></ref></ref-list><ack id="ak005"><sec id="s0005"><title>Acknowledgement</title><p id="p0020">None.</p></sec><sec id="s0010"><title>Conflict of interest</title><p id="p0025">No.</p></sec></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000524 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000524 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7138158
|texte= The impact of Coronavirus (COVID-19) on head and neck cancer patients’ care
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32247204" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |